During the last year, the project has focused on characterizing relationships between chemokine receptor expression and the functions of the subsets of helper T cells (CD4+ T cells) that express the receptors, in order to understand how the patterns of cell migration controlled through these receptors are integrated into the cells roles in immune and inflammatory responses. We have analyzed cells from peripheral blood of healthy donors and from cord blood using flow cytometry and cell sorting together with a variety of in vitro cellular and molecular assays to characterize the function of subsets of CD4+ T cells based on their chemokine receptor expression. We have also studied human tissue using immunohistochemistry. A principal accomplishment has been in the characterization of CD4+ T cells that can produce and secrete the proteins IL-17 and IL-22. These cells are now known as Th17 cells, a newly recognized lineage of activated and differentiated cells. Th17 cells have been implicated as critical cells in both host defense against some bacteria and in mediating tissue injury in a range of autoimmune diseases, such as Crohns disease, rheumatoid arthritis, and multiple sclerosis. We have found that all human Th17 cells express CCR6, which is the receptor for the chemokine CCL20. We hypothesize that blocking CCR6 might prevent trafficking of Th17 cells into tissue, and might, therefore, be effective therapy in treating autoimmune diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Intramural Research (Z01)
Project #
1Z01AI000749-08
Application #
7732519
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
8
Fiscal Year
2008
Total Cost
$1,059,248
Indirect Cost
City
State
Country
United States
Zip Code
Chung, Jo L; Sun, Jian; Sidney, John et al. (2010) IMMUNOCAT-a data management system for epitope mapping studies. J Biomed Biotechnol 2010:856842
Jacobson, Orit; Weiss, Ido D; Szajek, Lawrence et al. (2009) 64Cu-AMD3100--a novel imaging agent for targeting chemokine receptor CXCR4. Bioorg Med Chem 17:1486-93
Darash-Yahana, Merav; Gillespie, John W; Hewitt, Stephen M et al. (2009) The chemokine CXCL16 and its receptor, CXCR6, as markers and promoters of inflammation-associated cancers. PLoS One 4:e6695
Singh, Satya P; Zhang, Hongwei H; Foley, John F et al. (2008) Human T cells that are able to produce IL-17 express the chemokine receptor CCR6. J Immunol 180:214-21
Lupo, P; Chang, Y C; Kelsall, B L et al. (2008) The presence of capsule in Cryptococcus neoformans influences the gene expression profile in dendritic cells during interaction with the fungus. Infect Immun 76:1581-9
Menke, Julia; Zeller, Geraldine C; Kikawada, Eriya et al. (2008) CXCL9, but not CXCL10, promotes CXCR3-dependent immune-mediated kidney disease. J Am Soc Nephrol 19:1177-89
Rose, Jeremy J; Foley, John F; Murphy, Philip M et al. (2004) On the mechanism and significance of ligand-induced internalization of human neutrophil chemokine receptors CXCR1 and CXCR2. J Biol Chem 279:24372-86
Venkatesan, Sundararajan; Rose, Jeremy J; Lodge, Robert et al. (2003) Distinct mechanisms of agonist-induced endocytosis for human chemokine receptors CCR5 and CXCR4. Mol Biol Cell 14:3305-24
Farber, Joshua M; Berger, Edward A (2002) HIV's response to a CCR5 inhibitor: I'd rather tighten than switch! Proc Natl Acad Sci U S A 99:1749-51
Liao, Fang; Shirakawa, Aiko-Konno; Foley, John F et al. (2002) Human B cells become highly responsive to macrophage-inflammatory protein-3 alpha/CC chemokine ligand-20 after cellular activation without changes in CCR6 expression or ligand binding. J Immunol 168:4871-80

Showing the most recent 10 out of 12 publications